Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo.
Lu ZN, Shi ZY, Dang YF, Cheng YN, Guan YH, Hao ZJ, Tian B, He HW, Guo XL.
Biomed Pharmacother. 2019 Sep 27;120:109478. doi: 10.1016/j.biopha.2019.109478.

The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review.  Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH.  Cureus. 2019 Sep 4;11(9):e5563. doi: 10.7759/cureus.5563.

Outcomes of Prophylactic Pantoprazole in Adult Intensive Care Unit Patients Receiving Dialysis: Results of a Randomized Trial.  Schefold JC, Krag M, Marker S, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, Keus F, Guttormsen AB, Lange T, Møller MH; the SUP-ICU investigators.  Am J Nephrol. 2019;50(4):312-319. doi: 10.1159/000502732.

Subcutaneous pantoprazole in an elderly, palliative care patient.  Michelon H, Souchu H, Chauvron-Defilippi B, Lecoeur A, Villart M, Denis M.  BMJ Support Palliat Care. 2019 Aug 28. pii: bmjspcare-2019-001916. doi: 10.1136/bmjspcare-2019-001916.

Comparison of the gastric acid inhibition function among lansoprazole, pantoprazole, and their respective stereoisomers in healthy Chinese subjects.  Yu L, Sun LN, Zhang XH, Xu YH, Zhang HW, Shen YW, Xie LJ, Wang MF, Jiao HW, Li YQ, Wang YQ, Liu Y.  Int J Clin Pharmacol Ther. 2019 Nov;57(11):552-560. doi: 10.5414/CP203514.

Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial.  Marker S, Krag M, Perner A, Wetterslev J, Lange T, Wise MP, Borthwick M, Bendel S, Keus F, Guttormsen AB, Schefold JC, Rasmussen BS, Elkmann T, Bestle M, Arenkiel B, Laake JH, Kamper MK, Lång M, Pawlowicz-Dworzanska MB, Karlsson S, Liisanantti J, Dey N, Knudsen H, Granholm A, Møller MH; SUP-ICU trial investigators.  Acta Anaesthesiol Scand. 2019 Oct;63(9):1184-1190. doi: 10.1111/aas.13436.

Effects of Somatostatin Combined with Pantoprazole on Serum C-Reactive Protein and Intercellular Adhesion Molecule-1 in Severe Acute Pancreatitis.  Liu J, Wang G, Liu Y, Huang L, Xu X, Wang J.  J Coll Physicians Surg Pak. 2019 Jul;29(7):683-684. doi: 10.29271/jcpsp.2019.07.683.

Intragastric pH effect of 20mg of levo-pantoprazole versus 40mg of racemic pantoprazole the first seven days of treatment in patients with gastroesophageal reflux disease.  Remes-Troche JM, García García FD, Rojas-Loureiro G, Rivera-Gutiérrez X, Reyes-Huerta J, Amieva-Balmori M.  Rev Gastroenterol Mex. 2019 May 16. pii: S0375-0906(19)30052-7. doi: 10.1016/j.rgmx.2019.02.006.

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.  Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Cook Bruns N, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko AN, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S; COMPASS Investigators.  Gastroenterology. 2019 Aug;157(2):403-412.e5. doi: 10.1053/j.gastro.2019.04.041

Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection.  Lee BE, Kim GH, Song GA, Seo JH, Jeon HK, Baek DH, Kim DU.  Gut Liver. 2019 Jan 15;13(1):40-47. doi: 10.5009/gnl18222. 

Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer.  Koh JS, Joo MK, Park JJ, Yoo HS, Choi BI, Lee BJ, Chun HJ, Lee SW.  Cell Biosci. 2018 Sep 6;8:50. doi: 10.1186/s13578-018-0248-9.

Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR.  Dabrowski A, Štabuc B, Lazebnik L.  Prz Gastroenterol. 2018;13(1):6-15. doi: 10.5114/pg.2018.74556.

Safety

Anaphylactic reactions due to pantoprazole: case report of two cases.  Gupta PP, Bhandari R, Mishra DR, Agrawal KK, Bhandari R, Jirel S, Malla G.  Int Med Case Rep J. 2018 May 23;11:125-127. doi: 10.2147/IMCRJ.S153099.

Acute generalized exanthematous pustulosis caused by pantoprazole.  Schmitz B, Sorrells T, Glass JS.  Cutis. 2018 May;101(5):E22-E23

Anaphylaxis as a Rare Side Effect of Pantoprazole; a Case Report.  Faridaalaee G, Ahmadian Heris J.  Emerg (Tehran). 2018;6(1):e34